IV fluorescein administration

PreclinicalSmall molecule

IV fluorescein administration is one of 20 small molecule programs targeting Intraoperative. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

IntraoperativeCompleted

IntraoperativePreclinical

Completed

Competition

Competitive Landscape

24 competitors in Intraoperative

#DrugCompanyPhaseTrials

Zofran

Novartis

Approved

1 2

IC-Green

PProvepharm SAS

Approved

8 3

Ketalar

AAultman Health Foundation

Approved

5 4

Anerem

AAcacia Pharma Ltd

Approved

2 5

Reglan

IIstituto Clinico Humanitas

Approved

1 6

Ciprofol

Haisco Pharmaceutical Group Co., Ltd.

Phase 3

1 7

MS Contin

HHikma Pharmaceuticals LLC

Phase 2

1 8

Vancocin

HHikma Pharmaceuticals LLC

Phase 2

1 9

Marcaine

IInnocoll

Phase 2

1 10

Robinul

Jazz Pharmaceuticals

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Intraoperative1 trial

Assessment of Intraoperative Probe-based Confocal Laser Endomicroscopy in Digestive and Endocrine Surgery: a Pilot Study

Completed·IIHU Strasbourg·N/A·NCT02552004·15 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for IV fluorescein administration. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — IV fluorescein administration compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for IV fluorescein administration. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — IHU Strasbourg company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: IIHU Strasbourg

IV fluorescein administration

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Intraoperative1 trial

References

Drug Info

Quick Facts

Related News